When.com Web Search

  1. Ads

    related to: what is cetuximab for cancer

Search results

  1. Results From The WOW.Com Content Network
  2. Cetuximab - Wikipedia

    en.wikipedia.org/wiki/Cetuximab

    Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .

  3. Bi-specific T-cell engager - Wikipedia

    en.wikipedia.org/wiki/Bi-specific_T-cell_engager

    Another avenue for novel anti-cancer therapies is re-engineering some of the currently used conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach. [28] As of 2009, BiTEs against CD66e and EphA2 are being developed as well. [29]

  4. Panitumumab - Wikipedia

    en.wikipedia.org/wiki/Panitumumab

    In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations. [14] This was the result of a study, which demonstrated lack of benefit with Panitumumab in patients who carried NRAS mutations. [6]

  5. 3 biggest health hazards threaten all Americans, says oncologist

    www.aol.com/3-biggest-health-hazards-threaten...

    In terms of preventing cancer, heart disease and diabetes, Prato said that infectious diseases is a "very huge" risk factor that is often overlooked. In these cases, the patients may be prescribed ...

  6. HPV-positive oropharyngeal cancer - Wikipedia

    en.wikipedia.org/wiki/HPV-positive_oropharyngeal...

    The other agent that is widely used is Cetuximab, a monoclonal antibody directed at the epidermal growth factor receptor (EGFR). A 10% survival advantage at three years was noted when cetuximab was given concurrently with radiation (bioradiation). [169] Cetuximab trials were completed before knowledge of HPV status. [170]

  7. KRAS - Wikipedia

    en.wikipedia.org/wiki/KRAS

    A phase Ia/Ib dose escalation trial of the oral selective KRAS G12C inhibitor divarasib was published in 2023, where the drug was tested in non-small cell lung cancer, colorectal cancer, and other solid tumors with KRAS G12C mutations. [55] It continues in phase I and II studies for several cancer types as of August 2023. [56] [57] [58] [59]

  1. Ad

    related to: what is cetuximab for cancer